Seer Appoints Nicolas Roelofs to its Board of Directors
Seer, Inc. (Nasdaq: SEER), a leading life sciences company, has appointed Dr. Nicolas Roelofs to its Board of Directors. Dr. Roelofs brings over 35 years of operational and advisory experience in healthcare, life science tools, and diagnostics companies. His extensive background includes serving as President of the Life Sciences Group at Agilent Technologies and holding leadership positions at Bio-Rad Inc. and Stratagene Inc.
Dr. Roelofs expressed excitement about working with Seer, highlighting the company's unique capability to enable deep, unbiased proteomic analysis at unprecedented scale, speed, and robustness. He aims to leverage his industry experience to accelerate the adoption of Seer's Proteograph Product Suite and advance proteomics research.
Seer, Inc. (Nasdaq: SEER), una delle principali aziende nel settore delle scienze della vita, ha nominato Dr. Nicolas Roelofs nel suo Consiglio di Amministrazione. Il Dr. Roelofs porta con sé oltre 35 anni di esperienza operativa e di consulenza nel settore sanitario, negli strumenti per le scienze della vita e nelle aziende di diagnostica. Il suo ampio curriculum include il ruolo di Presidente del Life Sciences Group presso Agilent Technologies e posizioni dirigenziali in Bio-Rad Inc. e Stratagene Inc.
Il Dr. Roelofs ha espresso entusiasmo per la collaborazione con Seer, sottolineando l’unica capacità dell’azienda di consentire un'analisi proteomica profonda e imparziale su scala, velocità e robustezza senza precedenti. Il suo obiettivo è sfruttare la sua esperienza nel settore per accelerare l’adozione della Suite di Prodotti Proteograph di Seer e far progredire la ricerca nel campo della proteomica.
Seer, Inc. (Nasdaq: SEER), una empresa líder en ciencias de la vida, ha nombrado a Dr. Nicolas Roelofs para su Junta Directiva. El Dr. Roelofs aporta más de 35 años de experiencia operativa y de asesoría en el sector salud, herramientas de ciencias de la vida y compañías de diagnóstico. Su amplio currículum incluye haber sido Presidente del Grupo de Ciencias de la Vida en Agilent Technologies y haber ocupado cargos de liderazgo en Bio-Rad Inc. y Stratagene Inc.
El Dr. Roelofs expresó su entusiasmo por trabajar con Seer, destacando la capacidad única de la empresa para permitir un análisis proteómico profundo e imparcial a una escala, velocidad y robustez sin precedentes. Su objetivo es aprovechar su experiencia en la industria para acelerar la adopción de la Suite de Productos Proteograph de Seer y avanzar en la investigación proteómica.
Seer, Inc. (Nasdaq: SEER)는 주요 생명 과학 회사로서 Dr. Nicolas Roelofs를 이사회 멤버로 임명했습니다. Roelofs 박사는 헬스케어, 생명 과학 도구 및 진단 회사에서 35년 이상의 운영 및 자문 경력을 보유하고 있습니다. 그의 방대한 배경에는 Agilent Technologies의 생명 과학 그룹 회장과 Bio-Rad Inc. 및 Stratagene Inc.에서의 리더십 역할이 포함됩니다.
Roelofs 박사는 Seer와의 협력에 대한 기대감을 표명하며, 회사가 고유하게 제공하는 전례 없는 규모, 속도 및 견고함으로 깊고 편향되지 않은 단백질체 분석을 가능하게 하는 역량을 강조했습니다. 그는 자신의 산업 경험을 활용하여 Seer의 Proteograph 제품군의 채택을 가속화하고 단백질체 연구를 발전시키는 것을 목표로 하고 있습니다.
Seer, Inc. (Nasdaq: SEER), une entreprise leader dans le domaine des sciences de la vie, a nommé Dr. Nicolas Roelofs à son Conseil d'Administration. Dr. Roelofs apporte plus de 35 ans d’expérience opérationnelle et de conseil dans le secteur de la santé, des outils de sciences de la vie et des entreprises de diagnostic. Son vaste parcours comprend une présidence du Groupe des sciences de la vie chez Agilent Technologies et des postes de direction chez Bio-Rad Inc. et Stratagene Inc.
Dr. Roelofs a exprimé son enthousiasme à l'idée de travailler avec Seer, mettant en avant la capacité unique de l'entreprise à permettre une analyse protéomique approfondie et impartiale à une échelle, une vitesse et une robustesse sans précédent. Il vise à tirer parti de son expérience dans l'industrie pour accélérer l'adoption de la Suite de Produits Proteograph de Seer et faire progresser la recherche en protéomique.
Seer, Inc. (Nasdaq: SEER), ein führendes Unternehmen im Bereich der Lebenswissenschaften, hat Dr. Nicolas Roelofs in seinen Vorstand berufen. Dr. Roelofs bringt über 35 Jahre operative und beratende Erfahrung im Gesundheitswesen, in Lebenswissenschafts-Werkzeugen und in Diagnostikunternehmen mit. Zu seinem umfangreichen Hintergrund gehört die Tätigkeit als Präsident der Life Sciences Group bei Agilent Technologies sowie Führungspositionen bei Bio-Rad Inc. und Stratagene Inc.
Dr. Roelofs äußerte seine Begeisterung für die Zusammenarbeit mit Seer und hob die einzigartige Fähigkeit des Unternehmens hervor, eine tiefgehende und unparteiische proteomische Analyse in beispielloser Geschwindigkeit, Skalierung und Robustheit zu ermöglichen. Er beabsichtigt, seine Branchenerfahrung zu nutzen, um die Akzeptanz der Proteograph-Produktreihe von Seer zu beschleunigen und die Forschung im Bereich Proteomik voranzutreiben.
- Appointment of Dr. Nicolas Roelofs, an industry veteran with 35+ years of experience, to the Board of Directors
- Potential for accelerated growth and adoption of Seer's Proteograph Product Suite
- Addition of valuable insights and experience in the life science tools industry to Seer's leadership
- None.
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors.
“Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies,” said Omid Farokhzad, Chair and CEO of Seer. “His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome.”
“I’m excited to work with the Seer team and leverage my experience in the life science tools industry to drive their next phase of growth,” said Dr. Roelofs. “Seer uniquely enables deep, unbiased proteomic analysis at a scale, speed, and robustness previously not possible, and I believe they are at the leading edge of the expanding proteomics market. I look forward to sharing my insights and experience to help accelerate the adoption of the Proteograph Product Suite and transform our understanding of the proteome.”
Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc, and Chief Operating Officer at Stratagene Inc. He has previously served on the boards of several public and private companies including Olink Holding AB. Dr. Roelofs currently serves as chairman of Sengenics Corporation LLC, a board member of Velsera, LGC Group, and an advisory board member of 908 Devices Inc.
Dr. Roelofs holds a doctorate in organic chemistry from University of Nevada, Reno, a master’s degree in organic chemistry from Iowa State University, and a bachelor’s degree in chemistry, biology, and German from Simpson College.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact:
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d69812e6-055b-486d-9bda-37b742e0020a
FAQ
Who is the new Board member appointed by Seer (SEER)?
What is Dr. Nicolas Roelofs' background in the life sciences industry?
How might Dr. Roelofs' appointment impact Seer's (SEER) future growth?
What is Seer's (SEER) main product offering in the proteomics field?
